Publicacións en colaboración con investigadores/as de Fundación Hospital Alcorcón (30)

2024

  1. Recurrent alcohol-associated hepatitis is common and is associated with increased mortality

    Hepatology, Vol. 80, Núm. 3, pp. 621-632

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain

    Atherosclerosis, Vol. 375, pp. 38-44

  3. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

  4. Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survival

    Clinical and experimental rheumatology, Vol. 41, Núm. 8, pp. 1695-1703

2022

  1. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain

    Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 327-334

  2. Dyslipidemia observatory: Treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 253-260

  3. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  4. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

  5. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)

    Autoimmunity Reviews, Vol. 21, Núm. 10

2021

  1. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507] (Autoimmunity Reviews (2020) 19(5), (S1568997220300598), (10.1016/j.autrev.2020.102507))

    Autoimmunity Reviews

  2. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

2020

  1. Serodiscordant patients with systemic sclerosis: When antibody does not correspond to skin involvement

    Clinical and Experimental Rheumatology, Vol. 38, pp. S106-S114

  2. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation

    Autoimmunity Reviews, Vol. 19, Núm. 5

  3. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study

    PLoS ONE, Vol. 14, Núm. 9

  3. High delayed mortality after the first episode of Clostridium difficile infection

    Anaerobe, Vol. 57, pp. 93-98

  4. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry

    Clinical Rheumatology, Vol. 38, Núm. 4, pp. 1117-1124

2018

  1. Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study (Clinical Rheumatology, (2018), 37, 4, (999-1009), 10.1007/s10067-017-3936-7)

    Clinical Rheumatology